• Who we are
  • CD28 targeting
  • How it works

Scientific Advisory Board

Sebastian Amigorena, Ph.D.

Sebastian Amigorena, Ph.D.

Member of the French Academy of Sciences & Director of Immunology Department (INSERM U932, “Cancer Immunity”), Curie Institute, Paris, France.

Stephen M. Ansell, M.D., Ph.D.

Stephen M. Ansell, M.D., Ph.D.

Professor of Medicine, Mayo Clinic. Rochester, MN Chair, Lymphoma Group, Division of Hematology.

Michele (Miki) De Palma, Ph.D.

Michele (Miki) De Palma, Ph.D.

Associate Professor of cancer biology, Swiss Federal Institute of Technology of Lausanne (EPFL), Switzerland.

Professor Ignacio Melero, MD, PhD

Professor Ignacio Melero, MD, PhD

Co-Director dpt. Immunology and Immunotherapy Clinical and Cima Universidad de Navarra and Kidani Professor University of Oxford.

Back

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn